Article
As Congress moves toward possible approval of a new prescription drug program for Medicare recipients later this summer, how payments for cancer drugs and therapeutic services are determined may well hang in the balance.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.